Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

DNA replication at the heart of cell fate decisions and cancer development

Description du projet

Le rôle de la réplication de l’ADN sur le destin des cellules

La duplication fidèle du génome grâce à la réplication de l’ADN peut être compromise par différents facteurs de stress, avec des conséquences négatives pour l’intégrité génomique et le destin des cellules. Financé par le programme Actions Marie Skłodowska-Curie, le projet RepliFate a pour ambition d’étudier les mécanismes par lesquels la réplication de l’ADN affecte le destin des cellules et peut également mener au cancer ainsi qu’à d’autres maladies. Le projet dispensera une formation aux chercheurs européens et générera des connaissances fondamentales sur le processus de transformation maligne. L’identification des principaux acteurs de la réplication de l’ADN alimentera les futurs efforts de conception de traitements anticancéreux innovants.

Objectif

RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity.

RepliFate will investigate the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent malignant transformation. We will put DNA replication at the center stage as the driver of these processes and not a mere bystander, using recent technological to better understand the role of DNA replication as a determinant of cell fate and cancer. RepliFate links academia with industry and society and will provide new opportunities for innovation in one of the main societal challenges in human health, cancer. The scientific roots of RepliFate are set on the Horizon Europe Mission Cancer objectives Understand and Optimise. We will pave the way for the development of innovative cancer treatments exploring the links between DNA replication and cell fate, the immune response and unscheduled cell proliferation.

RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. Putting the focus on the fellows, we have combined our expertise to create an outstanding training program with the objective to generate leaders in the field with independent and out-of-the-box views to drive the knowledge of basic science to applications that will improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.

Coordinateur

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Contribution nette de l'UE
€ 755 913,60
Adresse
CALLE SERRANO 117
28006 Madrid
Espagne

Voir sur la carte

Région
Comunidad de Madrid Comunidad de Madrid Madrid
Type d’activité
Research Organisations
Liens
Coût total
Aucune donnée

Participants (7)

Partenaires (13)